全球胃癌市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球胃癌市場預計將從2025年的63.3億美元成長至2034年的159.8億美元，2026年至2034年的複合年成長率（CAGR）為10.84%。隨著醫療系統透過改善診斷、治療和疾病管理來應對胃癌帶來的負擔，該市場的重要性日益凸顯。胃癌是一種發生在胃部的疾病，其發病可能受到多種因素的影響，例如幽門螺旋桿菌感染、吸煙、飲食習慣以及某些遺傳易感性。人們對癌症症狀的認知不斷提高、診斷檢測的普及以及醫學影像技術的進步，都為疾病的檢測提供了支持。此外，高風險族群對癌症篩檢和早期診斷的日益關注，也促使醫療機構改善篩檢和治療流程。

市場成長主要得益於癌症治療的進步、癌症研究投入的增加以及標靶治療和免疫療法的開發。醫療機構正在採用內視鏡檢查、切片檢查和分子檢測等先進的診斷技術，以支持疾病分類和治療方案的發展。製藥公司正在推動針對特定腫瘤特徵和免疫通路療法的研究。生物標記的廣泛應用也有助於臨床醫生識別可能受益於特定治療的患者。此外，癌症診療基礎設施的擴建和專科診療服務的改善正在加速各地區胃癌診療服務的提供。

該市場的未來前景將受到早期檢測、個人化治療和創新癌症療法進展的影響。分子生物標記的研究有望改善標靶治療治療和免疫療法的患者選擇。診斷技術的進步和對風險因素認知的提高將有助於早期疾病的發現。聯合治療和精準腫瘤學方法也可能創造新的治療機會。然而，晚期診斷、治療費用和醫療服務可近性方面的差異仍然是重大挑戰。持續的研究、臨床路徑的改進以及提高獲得專業癌症護理服務的機會對於改善患者預後至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球胃癌市場：依疾病類型分類

• 市場分析、洞察與預測
• 腺癌
• 淋巴瘤
• 胃腸道基質腫瘤
• 類癌腫瘤
• 其他

第5章 全球胃癌市場：依治療類型分類

• 市場分析、洞察與預測
• 免疫療法
• 標靶治療
• 化療
• 放射線治療及手術

第6章 全球胃癌市場：依藥物類別分類

• 市場分析、洞察與預測
• PD-1/PD-L1抑制劑
• HER2拮抗劑
• VEGFR2拮抗劑
• 其他

第7章：全球胃癌市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第8章：全球胃癌市場：依通路分類

• 市場分析、洞察與預測
• 專科藥房和零售藥房
• 醫院藥房
• 其他

第9章 全球胃癌市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck & Co
  • Bristol Myers Squibb
  • AstraZeneca
  • Astellas Pharma
  • Roche
  • Eli Lilly
  • BeiGene
  • Daiichi Sankyo
  • Zymeworks
  • Amgen
  • Novartis
  • Pfizer
  • Sanofi
  • Takeda
  • Servier
  • Jiangsu Hengrui Medicine
  • Innovent Biologics
  • Eisai
  • Regeneron
  • Jiangsu Chia Tai Tianqing

The global gastric cancer market size is expected to reach USD 15.98 Billion in 2034 from USD 6.33 Billion in 2025, growing at a CAGR of 10.84% during 2026-2034.This market is gaining importance as healthcare systems continue to address the burden of gastric cancer through improved diagnosis, treatment, and disease management. Gastric cancer develops in the stomach and can be influenced by factors such as Helicobacter pylori infection, smoking, dietary habits, and certain genetic predispositions. Growing awareness of cancer symptoms, increasing access to diagnostic procedures, and improvements in medical imaging are supporting efforts to identify the disease. Greater attention to cancer screening and early diagnosis in high-risk populations is also encouraging healthcare providers to strengthen detection and treatment pathways.

Market growth is driven by advancements in oncology treatments, increasing investment in cancer research, and the development of targeted therapies and immunotherapies. Healthcare institutions are adopting improved diagnostic approaches, including endoscopy, biopsy, and molecular testing, to support disease classification and treatment planning. Pharmaceutical companies are investigating therapies that target specific tumor characteristics and immune pathways. The growing use of biomarkers is also helping clinicians identify patients who may benefit from particular treatment options. In addition, expanding oncology infrastructure and improved access to specialist care are supporting the availability of gastric cancer management services in different regions.

The future prospects of this market will be shaped by advances in early detection, personalized treatment, and innovative cancer therapies. Research into molecular biomarkers may improve patient selection for targeted treatments and immunotherapy. Improvements in diagnostic technologies and greater awareness of risk factors could support earlier identification of the disease. Combination therapies and precision oncology approaches may also create new treatment opportunities. However, late-stage diagnosis, treatment costs, and differences in healthcare access remain important challenges. Continued research, improved clinical pathways, and broader availability of specialized oncology services will be essential for strengthening patient outcomes.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

• Adenocarcinoma
• Lymphoma
• Gastrointestinal Stromal Tumor
• Carcinoid Tumor
• Others

By Treatment Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiation Therapy And Surgery

By Drug Class

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR2 Antagonists
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Specialty And Retail Pharmacies
• Hospital Pharmacies
• Others

COMPANIES PROFILED

• Merck & Co., Bristol Myers Squibb, AstraZeneca, Astellas Pharma, Roche, Eli Lilly, BeiGene, Daiichi Sankyo, Zymeworks, Amgen, Novartis, Pfizer, Sanofi, Takeda, Servier, Jiangsu Hengrui Medicine, Innovent Biologics, Eisai, Regeneron, Jiangsu Chia Tai Tianqing

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTRIC CANCER MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Adenocarcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gastrointestinal Stromal Tumor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Carcinoid Tumor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTRIC CANCER MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Radiation Therapy And Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTRIC CANCER MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. PD-1/PD-L1 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. HER2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. VEGFR2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTRIC CANCER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTRIC CANCER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Specialty And Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GASTRIC CANCER MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment Type
  • 9.2.3 By Drug Class
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment Type
  • 9.3.3 By Drug Class
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment Type
  • 9.4.3 By Drug Class
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment Type
  • 9.5.3 By Drug Class
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment Type
  • 9.6.3 By Drug Class
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GASTRIC CANCER INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck & Co
  • 11.2.2 Bristol Myers Squibb
  • 11.2.3 AstraZeneca
  • 11.2.4 Astellas Pharma
  • 11.2.5 Roche
  • 11.2.6 Eli Lilly
  • 11.2.7 BeiGene
  • 11.2.8 Daiichi Sankyo
  • 11.2.9 Zymeworks
  • 11.2.10 Amgen
  • 11.2.11 Novartis
  • 11.2.12 Pfizer
  • 11.2.13 Sanofi
  • 11.2.14 Takeda
  • 11.2.15 Servier
  • 11.2.16 Jiangsu Hengrui Medicine
  • 11.2.17 Innovent Biologics
  • 11.2.18 Eisai
  • 11.2.19 Regeneron
  • 11.2.20 Jiangsu Chia Tai Tianqing